Montiel-Jarquín ÄJ, Vázquez de Lara-Cisneros LG, López-Colombo A, Solís-Mendoza HA, Palmer-Márquez ML, Romero-Figueroa MS

Idioma: Español
Referencias bibliográficas: 42
Paginas: 436-442
Archivo PDF: 167.64 Kb.

RESUMEN

Antecedentes: La enfermedad por reflujo gastroesofágico (ERGE) se desarrolla cuando el contenido estomacal ocasiona síntomas molestos o complicaciones. Las formas leves son esofagitis no erosiva y erosiva; las graves, esófago de Barrett y adenocarcinoma esofágico. Las metaloproteinasas de la matriz degradan componentes de la matriz extracelular, y tienen un papel importante en la invasión tumoral y la metástasis. Objetivo: Relacionar la expresión de la metaloproteinasa-9 (MMP-9) en biopsias esofágicas de pacientes con formas leves y graves de ERGE. Método: Estudio transversal. Se determinó la expresión de MMP-9 en biopsias esofágicas de pacientes con ERGE grave y leve. Las variables fueron edad, sexo, diagnóstico, tabaquismo, alcoholismo, índice de masa corporal (IMC) y expresión de MMP-9. Se realizó estadística descriptiva, concordancia para el diagnóstico y prueba de ji al cuadrado. Resultados: 50 pacientes, 32 (64%) hombres y 18 (36%) mujeres, con edad media de 52.13 ± 14.75 años. Doce (24%) fumadores y 7 (14%) con alcoholismo. El IMC promedio fue de 26.71 ± 4.07 kg/m² (rango: 15-33); 40 (80%) eran obesos. La concordancia entre observadores para el diagnóstico histopatológico fue de 1.0, y de 0.84 para esofagitis. Veintisiete (54%) tuvieron esofagitis, 16 (32%) esófago de Barrett y 7 (14%) cáncer de esófago. Hubo expresión de MMP-9 en cuatro pacientes con esofagitis, cinco con esófago de Barrett y cinco con cáncer esofágico. Encontramos diferencia estadísticamente significativa entre la expresión de MMP-9 y el tabaquismo (p = 0.011) y el diagnóstico histopatológico (p = 0.052). Conclusiones: La expresión de MMP-9 es más frecuente en las formas graves que en las leves de ERGE.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Montiel-Jarquín AJ. Expresión de la metaloproteinasa 9 en pacientes con formas leves y graves de enfermedad por reflujo gastroesofágico. [Tesis de Maestría en Ciencias Médicas e Investigación, BUAP-IMSS]. Puebla, México; 2011.

2. Uscanga L, Nogueira-de-Rojas JR, Gallardo E, Bernal-Reyes R, González M, Ballesteros-Amozurrutia A. Gastroesophageal reflux disease. Gastroenterology Mexican association consensus. Mexican group for the GERD study. Rev Gastroenterol Mex. 2002;67:216-23.

3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R: [The Montreal definition and classification of gastroesophageal reflux disease: a global, evidence-based consensus paper]. Z Gastroenterol. 2007;45:1125-40.

4. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26.

5. Locke GR, III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-56.

6. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953-6.

7. Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J. 1982;126:46-8.

8. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl. 1989;156:7-13.

9. López-Colombo A, Morgan D, Bravo-González D, Montiel-Jarquín A, Méndez-Martínez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract. 2012;2012 606174.

10. Peralta-Pedrero ML, Lagunes-Espinosa AL, Cruz-Avelar A, Juárez-Cedillo T, Rodríguez-Moctezuma R, López-Carmona JM, et al. [Frequency of gastroesophageal reflux disease in elderly patients attending a family medicine clinic]. Rev Med Inst Mex Seguro Soc. 2007;45:447-52.

11. Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18:595-604.

12. Hui TT, Fass SM, Giurgiu DI, Iida A, Takagi S, Phillips EH. Gastroesophageal disease and nausea: does fundoplication help or hurt? Arch Surg. 2000;135:545-9.

13. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults — update 2004. Can J Gastroenterol. 2005;19:15-35. 12.

14. Chen M, Xiong L, Chen H, Xu A, He L, Hu P. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population- based study in South China. Scand J Gastroenterol. 2005;40:759-67.

15. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205-8.

16. Lim SL, Goh WT, Lee JM, Ng TP, Ho KY. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol. 2005;20:995-1001.

17. Segal I. The gastro-oesophageal reflux disease complex in sub-Saharan Africa. Eur J Cancer Prev. 2001;10:209-12.

18. Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905-14.

19. Flook N, Jones R, Vakil N. Approach to gastroesophageal reflux disease in primary care: putting the Montreal definition into practice. Can Fam Physician. 2008;54:701-5.

20. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease — current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-14.

21. Fass R, Hell RW, Garewal HS, Martinez P, Pulliam G, Wendel C, et al. Correlation of oesophageal acid exposure with Barrett’s oesophagus length. Gut. 2001;48:310-3.

22. Fass R, Ofman JJ. Gastroesophageal reflux disease — should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-9.

23. Fass R, Sampliner RE. Barrett’s oesophagus: optimal strategies for prevention and treatment. Drugs. 2003;63:555-64.

24. Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruïne A, et al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50:920-927.

25. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888-95.

26. Pedrazzani C, Catalano F, Festini M, Zerman G, Tomezzoli A, Ruzzenente A, et al. Endoscopic ablation of Barrett’s esophagus using high power setting argon plasma coagulation: a prospective study. World J Gastroenterol. 2005;11:1872-5.

27. Munitiz V, Martínez de Haro LF, Ortiz MA, Ruiz de AD, Molina J, Bermejo J, et al. Surgical treatment of high-grade dysplasia in Barrett’s esophagus. Cir Esp. 2007;82:214-8.

28. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003;76:S1367-9.

29. Van CE, Vantrappen G. Epidemiology and clinical aspects of esophageal cancer. J Belge Radiol. 1991;74:365-8.

30. Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353-60.

31. Gu ZD, Chen KN, Li M, Gu J, Li JY. Clinical significance of matrix metalloproteinase- 9 expression in esophageal squamous cell carcinoma. World J Gastroenterol. 2005;11:871-4.

32. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 1992;70:2747-53.

33. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56:190-6.

34. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Jr., et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006;12:1707-14.

35. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-503.

36. Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis. 2008;14:1114-21.

37. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol. 2007;13:676-82.

38. Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber Ch, Höfelmayr A, et. al. MMP-1 is a (pre-) invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Translational Med 2010;8:99.

39. Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer - an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:17-20.

40. Samantaray S, Sharma R, Chattopadhyaya TK, Dattta S, Gupta R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130:37-44.

41. Mukherjee S, Roth MJ, Dawsey SM, Yan W, Rodríguez-Canales J, Erickson HS, et al. Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Translational Med 2010;8:91.

42. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer. 2000;88:2201-9.